Jacob Bell
Lead Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. He can also be reached on Signal at realjacobbell.38.
1763 articles by Jacob Bell
-
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
June 26, 2026 -
To Wall Street, psychedelics biotechs are more teammates than rivals
June 24, 2026 -
How Kardigan spun deal leftovers into a $400M IPO
June 23, 2026 -
UniQure to file gene therapy for approval, reflecting major shifts at FDA
June 17, 2026 -
A new Westlake-backed biotech takes aim at migraines
June 17, 2026 -
Lilly scores early positive data for new JAK drug
June 15, 2026 -
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
June 12, 2026 -
Incyte to buy blood disorder drug in possibly $2B deal
June 8, 2026 -
Study data convince Lundbeck to push new migraine drug forward
June 5, 2026 -
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
June 2, 2026 -
Servier buys into muscular dystrophy with potentially $2.7B deal
June 1, 2026 -
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
May 29, 2026 -
Cardio drugmaker Kardigan plans to go public
May 27, 2026 -
Parkinson’s drug from Biogen, Denali comes up short
May 22, 2026 -
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid
May 21, 2026 -
A migraine drugmaker heads to the public markets through reverse merger
May 19, 2026 -
FDA approves AstraZeneca’s new kind of hypertension drug
May 18, 2026 -
A year after Vertex’s big launch, pain drug research faces a pivotal moment
May 12, 2026 -
Vertex earnings get muted investor response
May 5, 2026 -
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
May 1, 2026 -
Teva nabs experimental Tourette drug in $700M Emalex buyout
April 29, 2026 -
FDA approves Regeneron’s hearing loss gene therapy
April 23, 2026 -
Trump executive order lifts psychedelics biotechs
April 21, 2026 -
UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
April 17, 2026 -
Obsidian, Galera to advance cell therapy following reverse merger
April 15, 2026
